Genome-Wide Analyses of Prognostic and Therapeutic Alternative Splicing Signatures in Bladder Urothelial Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Apr 12

PMID 33842332

Citations 3

Authors

Zhongru Fan

Zhe Zhang

Chiyuan Piao

Zhuona Liu

Zeshu Wang

Chuize Kong

Affiliations

Soon will be listed here.

Abstract

Background: Alternative splicing (AS) is an indispensable post-transcriptional modification applied during the maturation of mRNA, and AS defects have been associated with many cancers. This study was designed to thoroughly analyze AS events in bladder urothelial carcinoma (BLCA) at the genome-wide level.

Methods: We adopted a gap analysis to screen for significant differential AS events (DASEs) associated with BLCA. DASEs with prognostic value for OS and the disease-free interval (DFI) were identified by Cox analysis. In addition, a differential AS network and AS clusters were identified using unsupervised cluster analysis. We examined differences in the sensitivity to chemotherapy and immunotherapy between BLCA patients with high and low overall survival (OS) risk.

Results: An extensive number of DASEs (296) were found to be clinically relevant in BLCA. A prognosis model was established based prognostic value of OS and DFI. CUGBP elav-like family member 2 (CELF2) was identified as a hub splicing factor for AS networks. We also identified AS clusters associated with OS using unsupervised cluster analysis, and we predicted that the effects of cisplatin and gemcitabine chemotherapy would be different between high- and low-risk groups based on OS prognosis.

Conclusion: We completed a comprehensive analysis of AS events in BLCA at the genome-wide level. The present findings revealed that DASEs and splicing factors tended to impact BLCA patient survival and sensitivity to chemotherapy drugs, which may provide novel prospects for BLCA therapies.

Citing Articles

EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML.

Brunmeir R, Ying L, Yan J, Hee Y, Lin B, Kaur H Leukemia. 2025; 39(3):650-662.

PMID: 39774797 PMC: 11879851. DOI: 10.1038/s41375-024-02509-y.

Alternative splicing regulation and its therapeutic potential in bladder cancer.

Li L, Jin T, Hu L, Ding J Front Oncol. 2024; 14:1402350.

PMID: 39132499 PMC: 11310127. DOI: 10.3389/fonc.2024.1402350.

Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer.

Ye F, Liang Y, Cheng Z, Liu Y, Hu J, Li W Front Immunol. 2022; 13:911902.

PMID: 35769470 PMC: 9234272. DOI: 10.3389/fimmu.2022.911902.

References

Cao R, Zhang J, Jiang L, Wang Y, Ren X, Cheng B . Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Oral Squamous Cell Carcinoma. Front Oncol. 2020; 10:1740. PMC: 7485395. DOI: 10.3389/fonc.2020.01740. View

Chatrikhi R, Mallory M, Gazzara M, Agosto L, Zhu W, Litterman A . RNA Binding Protein CELF2 Regulates Signal-Induced Alternative Polyadenylation by Competing with Enhancers of the Polyadenylation Machinery. Cell Rep. 2019; 28(11):2795-2806.e3. PMC: 6752737. DOI: 10.1016/j.celrep.2019.08.022. View

Sznajder L, Scotti M, Shin J, Taylor K, Ivankovic F, Nutter C . Loss of MBNL1 induces RNA misprocessing in the thymus and peripheral blood. Nat Commun. 2020; 11(1):2022. PMC: 7181699. DOI: 10.1038/s41467-020-15962-x. View

Piva F, Giulietti M, Burini A, Principato G . SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat. 2011; 33(1):81-5. DOI: 10.1002/humu.21609. View

DasGupta T, Ladd A . The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins. Wiley Interdiscip Rev RNA. 2011; 3(1):104-21. PMC: 3243963. DOI: 10.1002/wrna.107. View

Xie R, Chen X, Cheng L, Huang M, Zhou Q, Zhang J . NONO Inhibits Lymphatic Metastasis of Bladder Cancer via Alternative Splicing of SETMAR. Mol Ther. 2020; 29(1):291-307. PMC: 7791011. DOI: 10.1016/j.ymthe.2020.08.018. View

Yu L, Kim J, Jiang L, Feng B, Ying Y, Ji K . MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing. Nat Commun. 2020; 11(1):708. PMC: 7002374. DOI: 10.1038/s41467-020-14437-3. View

Fu X, Ares Jr M . Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet. 2014; 15(10):689-701. PMC: 4440546. DOI: 10.1038/nrg3778. View

Paschalis A, Sharp A, Welti J, Neeb A, Raj G, Luo J . Alternative splicing in prostate cancer. Nat Rev Clin Oncol. 2018; 15(11):663-675. DOI: 10.1038/s41571-018-0085-0. View

10.

Guo Z, Zhu H, Xu W, Wang X, Liu H, Wu Y . Alternative splicing related genetic variants contribute to bladder cancer risk. Mol Carcinog. 2020; 59(8):923-929. DOI: 10.1002/mc.23207. View

11.

Pique L, Martinez de Paz A, Pineyro D, Martinez-Cardus A, de Moura M, Llinas-Arias P . Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer. Oncogene. 2019; 38(45):7106-7112. DOI: 10.1038/s41388-019-0936-x. View

12.

Yang Q, Zhao J, Zhang W, Chen D, Wang Y . Aberrant alternative splicing in breast cancer. J Mol Cell Biol. 2019; 11(10):920-929. PMC: 6884705. DOI: 10.1093/jmcb/mjz033. View

13.

Baralle F, Giudice J . Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017; 18(7):437-451. PMC: 6839889. DOI: 10.1038/nrm.2017.27. View

14.

Chen K, Xiao H, Zeng J, Yu G, Zhou H, Huang C . Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. Clin Cancer Res. 2016; 23(13):3428-3441. PMC: 5440213. DOI: 10.1158/1078-0432.CCR-16-2020. View

15.

Ajith S, Gazzara M, Cole B, Shankarling G, Martinez N, Mallory M . Position-dependent activity of CELF2 in the regulation of splicing and implications for signal-responsive regulation in T cells. RNA Biol. 2016; 13(6):569-81. PMC: 4962813. DOI: 10.1080/15476286.2016.1176663. View

16.

Li Y, Yuan Y . Alternative RNA splicing and gastric cancer. Mutat Res Rev Mutat Res. 2017; 773:263-273. DOI: 10.1016/j.mrrev.2016.07.011. View

17.

Coomer A, Black F, Greystoke A, Munkley J, Elliott D . Alternative splicing in lung cancer. Biochim Biophys Acta Gene Regul Mech. 2019; 1862(11-12):194388. DOI: 10.1016/j.bbagrm.2019.05.006. View

18.

New J, Subramaniam D, Ramalingam S, Enders J, Ali Sayed A, Ponnurangam S . Pleotropic role of RNA binding protein CELF2 in autophagy induction. Mol Carcinog. 2019; 58(8):1400-1409. PMC: 6602857. DOI: 10.1002/mc.23023. View

19.

Zhang Y, Yan L, Zeng J, Zhou H, Liu H, Yu G . Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers. Oncogene. 2019; 38(40):6678-6695. DOI: 10.1038/s41388-019-0910-7. View

20.

Hu X, Harvey S, Zheng R, Lyu J, Grzeskowiak C, Powell E . The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing. Nat Commun. 2020; 11(1):486. PMC: 6981122. DOI: 10.1038/s41467-020-14304-1. View